Pediatric Dyslipidemia-Beyond Familial Hypercholesterolemia

Area of Science:

• Pediatric Endocrinology
• Cardiovascular Health
• Public Health

Background:

• Dyslipidemia prevalence is increasing in Canadian youth, often linked to obesity.
• This review covers hypertriglyceridemia, combined hyperlipidemia, and elevated lipoprotein(a) in children, excluding familial hypercholesterolemia.
• Obesity is a primary driver of mild to moderate hypertriglyceridemia in this demographic.

Purpose of the Study:

• To provide guidance on assessing and managing dyslipidemia in Canadian children and adolescents.
• To highlight the importance of comprehensive lipid profiling for atherosclerotic cardiovascular disease (ASCVD) risk stratification.
• To review current evidence and recommendations for non-familial hypercholesterolemia pediatric dyslipidemias.

Main Methods:

• Review of current literature and clinical guidelines pertinent to pediatric dyslipidemia.
• Analysis of recommended lipid markers for ASCVD risk assessment in youth.
• Discussion of lifestyle and pharmaceutical management strategies.

Main Results:

• Recommended ASCVD risk assessment includes low-density lipoprotein cholesterol and triglyceride levels.
• Non-high-density lipoprotein cholesterol and apolipoprotein B are valuable for risk stratification due to predictive power and convenience.
• Lipoprotein(a) measurement is not routine but considered in specific cases.

Conclusions:

• Lifestyle modifications including weight regulation, diet, and physical activity are foundational for managing pediatric dyslipidemia.
• Pharmaceutical interventions are reserved for high-risk cases unresponsive to lifestyle changes.
• Further research is needed to guide pharmaceutical management for pediatric hypertriglyceridemia and other non-FH dyslipidemias.